Biotechnology News

AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce...

Development of quantitative biomarker strategies for proteopathies through seragy’s proprietary SeRAS® technologyExpansion of the company’s laboratory and analytical capabilities with funding from...

LONDON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd., a biotechnology company pioneering extracellular matrix (ECM)-based drug discovery and development in oncology, fibrosis and...

Sapreme Therapeutics announces its lead Duchenne muscular dystrophy candidate, SPM-2551, and is presenting preclinical data at the OTS Annual Meeting.

TRexBio Announces Closing of Initial Public Offering

Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions ...

Mechelen, Belgium; October 13, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ:...

Mechelen, België; 13 oktober 2026, 22.01 CET; gereglementeerde informatie In het kader van het op 9 juni 2026 aangekondigde inkoopprogramma maakt Lakefront Biotherapeutics NV (Euronext & NASDAQ:...

SANGAMO THERAPEUTICS LAUNCHES AUCTION PROCESS FOR CLINICAL-STAGE CHRONIC NEUROPATHIC PAIN PROGRAM

The Elite Graft Program combines advanced biologic wound care, reimbursement support, and clawback protection to build provider confidence.